Myriad Genetics (MYGN) Depreciation & Amortization (CF) (2016 - 2025)
Myriad Genetics (MYGN) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $12.6 million as the latest value for Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 14.86% to $12.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.7 million through Dec 2025, down 12.25% year-over-year, with the annual reading at $53.7 million for FY2025, 12.25% down from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 was $12.6 million at Myriad Genetics, roughly flat from $12.6 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $19.4 million in Q1 2023, with the low at $12.6 million in Q3 2025.
- Average Depreciation & Amortization (CF) over 5 years is $14.6 million, with a median of $14.2 million recorded in 2021.
- The sharpest move saw Depreciation & Amortization (CF) crashed 62.85% in 2021, then surged 49.23% in 2023.
- Over 5 years, Depreciation & Amortization (CF) stood at $13.3 million in 2021, then increased by 3.01% to $13.7 million in 2022, then grew by 10.22% to $15.1 million in 2023, then decreased by 1.99% to $14.8 million in 2024, then decreased by 14.86% to $12.6 million in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $12.6 million, $12.6 million, and $14.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.